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Abstract
Identifying naturally-occurring neutralizing antibodies (NAb) that are cross-reactive against all global subtypes of HIV-1 is an
important step toward the development of a vaccine. Establishing the host and viral determinants for eliciting such broadly
NAbs is also critical for immunogen design. NAb breadth has previously been shown to be positively associated with viral
diversity. Therefore, we hypothesized that superinfected individuals develop a broad NAb response as a result of increased
antigenic stimulation by two distinct viruses. To test this hypothesis, plasma samples from 12 superinfected women each
assigned to three singly infected women were tested against a panel of eight viruses representing four different HIV-1
subtypes at matched time points post-superinfection (,5 years post-initial infection). Here we show superinfected
individuals develop significantly broader NAb responses post-superinfection when compared to singly infected individuals
(RR=1.68, CI: 1.23–2.30, p=0.001). This was true even after controlling for NAb breadth developed prior to superinfection,
contemporaneous CD4+ T cell count and viral load. Similarly, both unadjusted and adjusted analyses showed significantly
greater potency in superinfected cases compared to controls. Notably, two superinfected individuals were able to neutralize
variants from four different subtypes at plasma dilutions .1:300, suggesting that their NAbs exhibit elite activity. Cross-
subtype breadth was detected within a year of superinfection in both of these individuals, which was within 1.5 years of
their initial infection. These data suggest that sequential infections lead to augmentation of the NAb response, a process
that may provide insight into potential mechanisms that contribute to the development of antibody breadth. Therefore, a
successful vaccination strategy that mimics superinfection may lead to the development of broad NAbs in immunized
individuals.
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Introduction
Multiple studies have demonstrated the potential of HIV-
specific neutralizing antibodies (NAbs) to protect against infection
using nonhuman primate models [1,2]. However, it remains
unclear how to elicit a NAb response of sufficient breadth and
potency to protect humans against diverse circulating HIV-1
variants, which can differ by several orders of magnitude in
neutralization sensitivity [1,2]. Therefore, investigating naturally-
occurring antibody responses that can neutralize viruses across the
major viral subtypes remains a major focus of research [3]. In the
past few years, multiple HIV-specific broadly neutralizing
monoclonal antibodies have been isolated from HIV-infected
individuals with elite neutralizing activity [4–8]. This subset of
individuals comprises about 1% of chronically-infected individuals
and are considered elite neutralizers based on their ability to
potently neutralize viruses from multiple subtypes [9]. The
collection of broad monoclonal antibodies identified to date,
which were isolated more than a decade after initial HIV-1
infection in some cases, have undergone extensive somatic
hypermutation, a process that would be difficult to mimic with a
HIV-1 vaccine [2,10]. Also, these monoclonal antibodies have
been isolated from individuals who were presumably infected with
a single HIV-1 strain, although in most cases, the possibility of
superinfection (SI) was not addressed. Within singly infected
populations, NAb breadth has been positively associated with viral
diversity [11]. Therefore, individuals infected with multiple HIV-1
strains as a result of SI by a second source partner may generate
broadly NAbs in response to stimulation from both viruses.
Initially, it was hypothesized that SI resulted from a weak NAb
response that was unable to protect the individual from
reinfection. A small study of three SI cases and three viral strains
provided some support for this model [12]. However, in a larger
study using a panel of 16 viruses from a number of different
subtypes, Blish et al. showed no significant differences in the NAb
breadth or potency in six superinfected cases immediately before
acquisition of the second virus compared to 18 singly infected
controls at matched time points [13]. In this study, where the focus
was on correlates of protection from SI, the NAb repertoire and
breadth developed in the years following SI were not examined.
In the past year, two studies have provided evidence of a
broadening of the NAb response after SI. In a South African
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infection, broad and potent responses were detected 3 years post-
initial infection (32 of 42 heterologous viruses neutralized, some at
plasma dilutions .1:10,000) [14]. However, it was not possible to
determine whether SI is typically associated with a broad NAb
response or if this single case was merely coincidental. Powell et al.
aimed to address this question by measuring the difference in NAb
responses from four superinfected cases and 23 singly infected
controls against seven regional primary isolates from Cameroon
and two subtype B viruses [15]. They showed that the average
change in NAb breadth and potency between pre-SI and post-SI
evaluations for superinfected cases was significantly greater than
that of non-superinfected controls [15]. While this analysis
provides some evidence that superinfected individuals develop
broader NAb responses than singly infected individuals, the results
have to be interpreted in the context of a number of limitations in
the cohort studied, including an imbalanced distribution of cases
and controls where matching was based on two groups of controls
rather than an equal ratio of individuals. More significantly, since
seroconversion dates were unknown for many individuals, the
control groups were assigned based on the time each case had
participated in the study, rather than how long they had been
infected. Therefore, time since infection, which has been strongly
associated with the development of NAb breadth [16–18], could
not be accounted for in this analysis. Furthermore, due to the small
number of superinfected cases, the investigators were unable to
control for potential confounding factors such as CD4
+ T cell
count and viral load, which also impact NAb breadth [11,16–19].
Nonetheless, these cases are intriguing and highlight a need for a
controlled study with greater numbers of superinfected cases with
appropriately matched controls.
We have previously identified 12 superinfected individuals from
a cohort of high-risk women in Mombasa, Kenya by comparing
partial env and gag sequences over a 5-year period beginning with
initial infection [20–22]. This cohort includes individuals initially
infected by viruses from multiple subtypes (A, C, and D), and
subsequently reinfected by intra or intersubtype viruses. Here we
describe the results from our nested cohort study in which we
tested the hypothesis that superinfected individuals develop
broader and more potent NAb responses compared to non-
superinfected individuals as a result of increased antigenic
stimulation by two distinct viruses. Our findings illustrate that SI
leads to an augmentation of the NAb response and thus, provides
significant support for SI as a useful model for studying the
development of the NAb response to diverse HIV-1 antigens.
Results
Cohort characteristics
The 12 cases of SI demonstrated considerable heterogeneity
with respect to the temporal occurrence and virologic factors
related to their superinfections (Figure 1) [20–22]. Some women
were superinfected soon after initial infection, while others became
superinfected much later during chronic infection (range: ,2
months to 5 years post-initial infection), with the median
occurrence at 1.72 years post-initial infection. Eight individuals
(60%) experienced an increase in viral load after SI; in three cases
the increase was very small (,0.5 log10 copies/ml), while in the
remaining five the mean change was 1.08 log10 copies/ml. Similar
numbers of women had inter and intrasubtype superinfections
based on env and gag sequences, and all women were infected with
at least one subtype A virus, the dominant subtype in Kenya [23].
Based on the longitudinal analyses previously described [20–22],
the superinfecting strain persisted in combination with the initial
virus in seven (58%) of the women, whereas it appeared to have
largely replaced the initial virus in the other five (42%) (Figure 1).
Three non-superinfected individuals, selected from a pool of
women identified as singly infected in prior screens [20–22], were
matched to each superinfected case by the initial infecting virus
subtype, time post-initial infection, and sample availability. NAb
breadth and potency were analyzed both pre and post-SI. The
pre-SI time point for each superinfected case and her matched
controls varied in relation to initial infection depending on the
timing of the SI event. The post-SI time point was evaluated at a
single time point for all individuals an average of 5 years post-
initial infection, when all 12 cases had been superinfected for at
least 1 year. The single post-SI time point enabled us to draw
comparisons across the entire cohort after the development of the
NAb response to both the initial and superinfecting viruses, yet
before the onset of overt immunodeficiency [16,24–26]. Superin-
fected women had significantly lower mean viral loads than singly
infected women pre-SI (Log10VL: 4.24 vs. 4.79, respectively;
p=0.034), but were comparable post-SI (Log10VL: 4.78 vs. 4.89,
respectively; p=0.699). Both groups also had similar mean CD4+
T cell counts post-SI (370 vs. 380; p=0.886). Insufficient CD4+ T
cell count data were available for the cohort at the time points
prior to SI for analysis. Superinfected women had unprotected sex
on average 22% of the time compared to 33% of the time for non-
superinfected women (p=0.175) and both groups had similar
numbers of partners per week (0.66 vs. 0.49, respectively;
p=0.069). All individuals in this study were ARV naı ¨ve at the
time points examined.
Comparison of NAb breadth and potency in
superinfected and singly infected women after SI
Eight viruses from subtypes A, B, C, and D that exhibit varying
degrees of neutralization sensitivity to monoclonal antibodies as
well as pooled plasma derived from HIV-1 infected individuals in
Kenya were used to measure NAb breadth and potency both pre
and post-SI (Table 1). Seven of the eight viruses were isolated from
individuals during acute infection, and the majority were Tier 2
variants [27].
Author Summary
A broad and potent antibody response is considered
essential for an effective HIV-1 vaccine that will protect
against diverse circulating strains. Consequently, there is
great interest in both the host and viral factors that impact
the development of the neutralizing antibody (NAb)
response in natural HIV-1 infections. HIV-infected individ-
uals who become superinfected with a second virus from a
different source partner represent unique cases for
studying the antibody response, as superinfection reflects
exposure to different HIV-1 antigenic variants, and hence
may provide insight into the development of broadly
NAbs. In support of this model, we show here that
superinfected individuals develop broader and more
potent NAb responses than singly infected individuals, a
result that is likely due to the increased antigenic
stimulation from two viruses compared to one. Our
findings remained unchanged after controlling for other
factors that have been shown to influence the NAbs
response, such as CD4+ T cell count and viral load. This
study demonstrates that superinfection yields antibodies
that have the capacity to recognize diverse circulating HIV-
1 variants. Therefore, further characterization of these
superinfected individuals’ NAb responses could lead to
novel insights into pathways that elicit broadly NAbs.
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virus influences the development of NAb breadth and potency, we
first tested all superinfected cases and matched controls at a time
point post-SI, approximately ,5 years post-initial infection (median
time after initial infection: 5.01 years, Range: 2.8–8.1 years)
(Figure 2). Overall, the Tier 1 viruses that were neutralization
sensitive (SF162 and Q461d1) had the highest median IC50 values
(606 and 583, respectively) for the cohort as a whole, while the
median IC50s for the six Tier 2 viruses were all below 300.
Geometric mean IC50s averaged across the entire panel were
significantly different between superinfected casesand singly infected
individuals (326.19 vs. 193.33, respectively; p=0.038). Furthermore,
differences in neutralization potency between individual superin-
fected cases and matched controls are evident, most notably with the
more neutralization resistant viruses such as Q769.b9 and
Q259.d2.26 (Figure 2). Breadth and potency scores were calculated
by normalizing the IC50 of each plasma-virus pair to the cohort
medianIC50,asdescribed[13].ThemeanNAbbreadthscoreofthe
12 superinfected women was 5.75, while the mean breadth score of
the 36 non-superinfected women was 3.42 (Figure 3A). Superinfect-
ed women had, on average, 1.68 (CI: 1.23–2.30, p=0.001) times
greater breath than non-superinfected women (Table 2). Similarly,
the mean potency score in superinfected women was higher than
singly infected women (17.25 vs. 11.84, respectively) (Figure 3B), and
superinfected women had 1.46 (CI: 1.03–2.06, p=0.033) times
greater potency than the non-superinfected group (Table 2).
Comparison of NAb breadth and potency in
superinfected and singly infected women before SI
In order to determine whether the greater NAb breadth
exhibited by superinfected women was independent of any effect
of the NAb breadth developed prior to the SI event, we assessed
the NAb responses elicited by the initial virus prior to SI in each
individual (Figure 4). Viruses that were neutralization sensitive
(SF162 and Q461d1) had the highest median IC50 values (158
and 130, respectively), followed by two Tier 2 viruses, DU156.12
and QD435.100M.a4 (108 and 61, respectively). The cohort
median IC50s was 50 for the other four Tier 2 viruses, with only a
few individuals able to neutralize these viruses at greater than 50%
at the lowest dilution tested. Overall, the geometric mean IC50s
averaged across the entire panel were not significantly different
between superinfected cases and singly infected controls (98.16 vs.
86.02, respectively; p=0.378). The mean NAb breadth score for
superinfected women was 4.30, but only 2.80 for non-superinfect-
ed women (Figure 3C). Superinfected women had, on average,
1.50 (CI: 1.05–2.14, p=0.03) times greater breath than non-
superinfected women at the matched pre-SI time points. However,
upon adjusting for contemporaneous viral load, which differed
between the two groups and is a correlate of NAb breadth [16,19],
the difference in breadth at this time point was attenuated and no
longer statistically significant (RR=1.45, CI: 0.97–2.16,
p=0.067). We observed comparable mean potency scores
between superinfected and singly infected women (14.39 vs.
13.93, respectively) (Figure 3D), that were not significantly
different in our univariate analysis (p=0.447), nor after adjusting
for contemporaneous viral load (p=0.195).
Multivariate modeling of the NAb breadth and potency
after SI
We performed a multivariate analysis to examine the relation-
ship between SI status and the NAb response while adjusting for
breadth/potency scores pre-SI as well as contemporaneous viral
Figure 1. Viral characteristics of 12 cases of SI. Subject IDs are shown to the left with time since initial infection plotted at the bottom. Red bars
denote the interval during which SI occurred, with closed circles representing the last time point in which SI was last undetected and the time point
at which SI was first detected. Black triangles mark the midpoint of this interval, which was used as the estimated time of the SI event. The individual’s
viral load (log10 copies/ml) at the corresponding time points is noted above each red bar, with ( ˆ) denoting increases in viral load .0.5 log10 copies/ml.
Subtyping in the two columns on the right are based on env sequences. However, the data for those individuals with an (*) by their superinfecting
virus subtype based on gag sequences alone as the superinfecting env sequence was not detected at time points tested. Virus outcome was based
on the longitudinal analyses previously described [20–22]. Persistence was defined as the detection of co-existence of the superinfecting virus with
the initial virus following its introduction, while we classified replacement superinfections as the dominance of the superinfecting virus based on lack
of detection of the initial virus post-SI [22].
doi:10.1371/journal.ppat.1002611.g001
HIV-1 Superinfection and Antibody Response
PLoS Pathogens | www.plospathogens.org 3 March 2012 | Volume 8 | Issue 3 | e1002611load and CD4
+ T cell count. We found that none of these factors
individually had a major impact on the association between SI and
NAb breadth post-SI, as our estimate of 1.68 remained statistically
significant with estimates ranging between 1.56 to 1.70 (Table 2).
Adjusting simultaneously for all three variables similarly did not
substantially change the original estimate (RR=1.51, CI: 1.01–
2.25, p=0.040) (Table 2). The multivariate analysis for NAb
potency post-SI after adjusting for these same three variables
yielded a higher estimate, changing from 1.46 to 1.68, illustrating
that the association between SI and potency is stronger once these
variables are accounted for.
We next performed the same analysis with a modified breadth
scoring method previously used by Simek et al. and the Center for
HIV-1 AIDS Vaccine Immunology (CHAVI) for Protocol 008 [9].
Using this method, we similarly found that superinfected
individuals demonstrated greater breadth than singly infected
individuals post-SI (mean scores: 0.75 vs. 0.57, respectively;
p=0.002) (Table S1). Pre-SI breadth also showed differences
between superinfected and non-superinfected individuals (mean
scores: 0.46 vs. 0.34, respectively; p=0.019), but this difference
did not remain significant after adjusting for contemporaneous
viral load (p=0.435). To determine if our results were sensitive to
the exclusion or inclusion of a particular virus in the panel, we
performed a stepwise sensitivity analysis where we assessed
breadth after removing one virus at a time and also with various
combinations of viruses from the original 8-virus panel (e.g. only
subtype As, only viruses with a particular neutralization profile,
such as resistance to b12 or pooled plasma). Overall, the results
were similar to our original finding, with estimates from regression
analysis ranging from 1.36 to 1.91, all of which represent
statistically significant differences between the two groups (Table
S1). In addition, estimates using percent neutralization at a fixed
dilution of plasma (1:100, 1:200 or 1:400), as was used in prior
studies [9,15,28], yielded similar results with statistically significant
point estimates ranging from 1.55 to 1.70 (Table S2). Moreover,
breadth scores calculated from the percent neutralization at a
single dilution were also highly correlated with the breadth scores
based on IC50s calculated from full neutralization curves with all
six serial dilutions (Spearman’s rho range: 0.76–0.88, all with
p=,0.0005) (Table S3).
Longitudinal analysis shows NAb breadth developed
early after SI in women with the broadest responses
To determine whether SI led to a rapid enhancement of the
NAb response, we analyzed longitudinally banked plasma samples
from the two women with the broadest responses post-SI (QA013
and QB850) against the same 8-virus panel described above,
beginning with the time point available following the initial
detection of SI (Figure 5). We found that QA013, who was
superinfected ,11 months after her first infection, experienced a
boost in NAb activity immediately following SI (pre-SI geometric
mean (GM) IC50=118, range: 50–308, ,0.6 years post-SI GM
IC50=299, range: 79–1073). Her response continued to increase
in potency, with a GM IC50 of 567 at ,4.2 years post-SI (range:
224–1311). QB850, who was superinfected ,2 months after her
first infection, at first displayed modest cross-subtype activity ,1
year post-SI (GM IC50=146, range: 65–428) before gradually
developing elite activity around ,2.2 years post-SI (GM
IC50=451, range: 168–2268), which was ,2.3 years post-initial
infection. Overall, these data demonstrate that QB850 and
QA013 developed cross-subtype neutralization within 1 year
following SI, with two different trajectories that both led to elite
NAb activity. To further assess the breadth of the response of these
two individuals, additional viruses were tested, with an emphasis
on subtypes that were represented by a single virus in our screen
(subtypes B and D). There are limited options for subtype D
viruses, but we chose a neutralization resistant variant from the
Mombasa cohort, QB857. Three subtype B viruses JR-CSF,
6535.3 and CAAN5342.A2, were chosen based on their use in a
prior screen to define elite neutralizers [9]. Both QA013 and
QB850 plasma samples from 5 years post-initial infection
neutralized all four of these viruses, with IC50s ranging from
72–810. The IC50 values we observed for QA013 and QB850
against the subtype B viruses (JR-CSF: 207 and 163, 6523.3: 322
and 810, CAAN5342.A2: 127 and 106, respectively) were all
comparable or above the cohort GM IC50s observed in the elite
neutralizer screen [9]. However, it was not possible to directly
compare all of our IC50s to the top 1% of elite neutralizers
identified in that study because the IC50 values for those
individuals against these viruses were not presented.
Table 1. Neutralization sensitivities of eight HIV-1 envelope variants of different subtypes.
Pseudovirus
Subject/transmission
route
Time
postinfection
a
(days) Subtype Tier
b
IC50 for
pooled
plasma
c IC50 (ug/ml) for indicated monoclonal
Source or
reference
VRC01 PG9 b12 2F5 4E10
Q461.d1 female/heterosexual 17 A 1B 489 0.29 1 1 0.18 0.11 43
Q769.b9 female/heterosexual 56 A 2 52 0.17 0.05 .20 20 .20 43
Q259.d2.26 female/heterosexual 17 A 2 59 0.55 .1 .20 .20 .20 43
Q842.d16 female/heterosexual 49 A 2 136 0.51 0.08 .20 .20 14.6 43
QD435.100M.a4 female/heterosexual 100 D 2 69 0.36 .10 5.74 0.76 2.58 43
QC406.70M.f3 female/heterosexual 70 C 2 119 .1 0.15 .20 .20 .20 44
DU156.12 female/heterosexual 28 C 2 195 0.31 0.16 3.13 .20 1.57 46
SF162 male/MSM
d Chronic B 1A 583 0.6 .1 0.01 4.5 8 45
aThis estimate is based on published data and methods for estimating time of infection as described [54].
bTier designation is based on available data [27] or, in some cases, on extrapolation using the IC50 values shown here.
cPooled plasma was from 30 HIV-positive Kenyan individuals from the cohort.
dMSM, men who have sex with men.
doi:10.1371/journal.ppat.1002611.t001
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In this study, we tested the ability of antibodies present in
superinfected and singly infected women to neutralize a spectrum
of circulating HIV-1 variants and thus, discern whether antigenic
stimulation by two viruses compared to one has an effect on the
subsequent NAb response. Our results demonstrate that the NAb
response of superinfected women is significantly broader and more
potent than that of singly infected women when compared at
matched time points. These data suggest that SI elicits a
substantial enhancement of the NAb response with regards to
cross-reactivity in the years following reinfection. This conclusion
is supported by our analysis controlling for NAb breadth/potency
prior to SI and clinical measures that are associated with NAb
breadth such as CD4+ T cell count and viral load [11,16–19].
Therefore, the study of superinfected individuals may yield
additional insights into the development of broad and potent
NAb responses to diverse HIV-1 antigens.
The majority of superinfected individuals exhibited breadth and
potency scores that were greater than the average of their matched
controls post-SI. Among the SI cases, the three women with the
most potent responses (QB850, QA013, QC885) experienced
intersubtype superinfections that were characterized by persistence
of both the initial and superinfecting viruses. While we attempted
to parse out which factors relating to SI may be influencing the
generation of a broad response, we were unable to do so
conclusively due to a limited sampling of 12 cases (data not
shown). However, the characteristics of these three women
suggests that continuous stimulation by two distinct viruses from
different subtypes may be critical to the induction of broad NAbs.
Still, other factors, including the antigenic nature and replication
potential of the infecting viruses, may also be important.
Conversely, we found a minority of superinfected individuals
(QB045, QC858, QD022) exhibited breadth and potency scores
that were lower than that of the average from their matched
controls. As all three had a CD4+ T cell count .400 post-SI, it is
Figure 2. Post-SI neutralization profiles for superinfected and non-superinfected plasmas tested against heterologous HIV-1
variants. Subject IDs are shown to in the first column. Superinfected individuals denoted with borders and ‘‘SI’’ before ID number, with the three
matched controls listed below. The next columns lists the years post initial infection (YPI*) that was tested, which was used to match cases and
controls. The following columns list the years post-SI (YPSI
#) for each superinfected case. All samples were chosen near 5 years post-initial infection.
However, some samples were taken 1–2 years before or after this time point because of sample availability. Subsequent columns contain the IC50 for
each plasma-virus pair, which is the reciprocal dilution of plasma that led to a 50% reduction in infectivity. Plasma samples that showed neutralization
below the limit of detection were designated an IC50 value of 50, the midpoint between our starting dilution (1:100) and 0. IC50s are shown as a heat
map to represent increasing neutralization sensitivity, with white boxes for values below 100, light blue boxes for values between 101 and 300, darker
blue boxes for values between 301 and 500, and the darkest blue boxes for values greater than 501. The NAb response breadth and potency scores
that are shown here were calculated after taking the average log2 IC50s from the two experiments.
doi:10.1371/journal.ppat.1002611.g002
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T cell help that could arise at terminal stages of infection. Some
potentially informative features of these cases are that two of the
three (QB045 and QD022) are the only individuals in the cohort
who became superinfected late after initial infection (.4 years
post-initial infection), suggesting that perhaps the timing or
duration of either or both infections may be critical to the
development of NAb breadth. Moreover, in QD022 and QC858
the superinfecting variant became dominant as the initial virus
could no longer be detected post-SI, at least at levels captured by
Sanger sequencing, suggesting that continued antigenic stimula-
tion by both infecting viruses may be important in augmenting the
NAb response. Additional studies that include deep sequencing of
viruses in tissue and plasma would be one starting point to further
explore this hypothesis.
In one individual, QA413, multiple Tier 2 viruses were
neutralized prior to SI, while the Tier 1 viruses (SF162 and
Q461d1) were not. This may suggest that there are unique
epitopes common to the two Tier 1 viruses that are not present in
the Tier 2 viruses or vice versa. In the case of Q461d1, the
envelope is highly sensitive to neutralization because of
conformational changes that expose multiple epitopes [29].
However, we have found that Q461d1 is relatively insensitive
to neutralization by the PGT-type antibodies that recognize a
quaternary structure that includes an Asn at amino acid position
160 (unpublished). SF162 is also not recognized by PG9 and
Figure 3. Summary of differences in NAb breadth and potency scores between superinfected and non-superinfected women. Each
case and the three matched controls are denoted by a single color. Mean scores shown with horizontal bar. Breadth and potency comparisons post-SI
are shown in panels (A) and (C), respectively. Breadth and potency comparisons pre-SI are shown in panels (B) and (D), respectively.
doi:10.1371/journal.ppat.1002611.g003
Table 2. Association between NAb breadth and superinfection.
Breadth Potency
Univariate RR 95% CI P value Ratio 95% CI P value
1.68 1.27, 2.30 0.001 1.46 1.03, 2.06 0.033
Multivariate adjusting for aRR 95% CI P value aRatio 95% CI P value
Breadth/potency pre-SI 1.56 1.11, 2.18 0.009 1.40 1.05, 1.86 0.020
Contemporaneous viral load 1.68 1.22, 2.31 0.001 1.54 1.07, 2.25 0.022
Contemporaneous CD4+ T cell count 1.70 1.28, 2.25 ,0.001 1.63 1.10, 2.43 0.016
All of the above 1.51 1.01, 2.25 0.040 1.68 1.28, 2.20 ,0.001
doi:10.1371/journal.ppat.1002611.t002
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[4,8]. Interestingly, the virus that initially infected QA413
encodes an Asn at position 160, while the superinfecting virus
encodes a Lys, perhaps suggesting that PGT-like antibodies could
contribute to the antibody response in this woman. Mapping
studies to define the epitope specificity will be needed to
understand the unusual pattern of virus neutralization observed
in QA413 pre- and post-SI.
Figure 5. Elite neutralizers QB850 and QA013 develop breadth within 1 year following SI. The kinetics of the NAb responses for QB850
(A) and QA013 (B) are shown versus years post-initial infection. Viruses of the same subtype are shown with the same line color. Geometric mean
IC50s for the entire 8-virus panel are shown in the dashed black lines. The approximate time of SI, calculated as described in Figure 1, is indicated by
the corresponding red arrows for each individual.
doi:10.1371/journal.ppat.1002611.g005
Figure 4. Pre-SI neutralization profiles for superinfected and non-superinfected plasmas tested against heterologous HIV-1
variants. The layout for this figure is as described in the legend for Figure 2. Heterologous HIV-1 variants tested were the same as in the post-SI
screen. IC50s are similarly shown with darker colors denoting greater neutralization sensitivity. Plasmas not tested are indicated by a pair of dashes.
doi:10.1371/journal.ppat.1002611.g004
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a panel of heterologous viruses. In a prior study, the responses to
autologous viruses were examined in five of these individuals [13].
Interestingly, one of the elite neutralizers, QA013, developed very
high titers against her superinfecting virus, with IC50 values
.1,800 (range: 1,000–25,000+) to all four SI variants cloned at
,5 years post-SI (6.3 years post-initial infection). The other four
superinfected individuals, who did not develop elite responses, had
autologous responses that ranged from ,100 to 10,000. There was
insufficient data to determine if there was an association between
autologous and heterologous responses.
It is difficult to directly compare the NAb responses of the
superinfected women to broad neutralizers identified in other
studies because there is no standard for quantifying NAb breadth
against HIV-1. We addressed this issue by using a diverse panel of
viruses weighted towards Tier 2 variants and several alternate
breadth scoring methods, which showed that no single virus drove
the association observed between SI and NAb breadth and that
our conclusion is the same irrespective of the scoring method used.
Simek et al. previously defined elite activity as ‘‘the ability to
neutralize, on average, more than one pseudovirus at an IC50 titer
of 300 within a clade group and across at least four clade groups
[9].’’ While we were unable to completely satisfy these criteria
since our 8-virus panel included only single variants of subtypes B
and D, we still found that the two superinfected individuals
(QA013 and QB850) with the broadest responses could neutralize
at least two viruses in subtypes A and C, as well as both single
viruses tested from subtypes B and D at an IC50 titer greater than
300, supporting the characterization of these individuals as elite
neutralizers. Notably, plasma antibodies from QB850 neutralized
viruses from all four subtypes tested at IC50 values greater than
600, more than 2-fold higher than the bar set for elite neutralizers
[9]. Furthermore, the responses of these two women were greater
than those found in a similar screen of 70 singly infected women in
this cohort at ,5 years post-initial infection [11], with some
observed IC50 titers against Tier 2 viruses 6-fold more potent than
those of the top 10% of the singly infected women (data not
shown). Although we had limited opportunities to directly
compare the responses of the superinfected individuals studied
here and individuals identified as elite neutralizers by Simek et al.
in the IAVI cohort, we did find that the SI cases had IC50 values
that were either comparable or above the cohort GM IC50 for the
three viruses tested in common between the studies. Together,
these data suggest that 2 of the 12 individuals from our SI cohort
developed NAbs that exhibit elite activity. This is a remarkable
fraction (17%) of individuals with elite activity, although because
of differences between screening methods, it is difficult to compare
this to the 1% of presumably singly infected elite neutralizers
reported previously by Simek et al.
In a prior study that examined four cases of SI, a greater
increase in NAb breadth post-SI among superinfected individuals
compared to singly infected individuals was also observed [30].
However, it is hard to compare their data with our own, as the
previous study used randomly chosen primary isolates for
measuring breadth in a cohort with unknown seroconversion
dates. It is also interesting to note that this previous study observed
a decrease in viral load in three of the four superinfected cases
studied at a time point post-SI, two of which had undetectable
viral loads. Such a significant drop in viral load has not been
previously reported for cases of SI [31]. In contrast, we observed
an increase or no change in viral load in the majority of
superinfected women examined. This is consistent with the
observation that viral load is highly correlated with NAb breadth
[11,16]. However, after adjusting our breadth score analysis for
contemporaneous viral load, the estimate of 1.68 was unchanged,
while adjusting for this variable caused an increase in our estimate
for differences in potency. This would imply that breadth in these
superinfected cases alone cannot be explained entirely by an
increase in viral load following SI, but rather suggests that
stimulation from antigenically distinct viruses may contribute to
the development of potency.
Finally, we found evidence of cross-subtype breadth, including
detectable neutralization of viruses from four different subtypes in
the two women with elite NAb responses within 1 year of their SI.
Because both of these individuals were superinfected soon after
their initial infection, these cross-subtype responses arose relatively
soon after HIV-1 seroconversion. Indeed, by 2 years after their
initial infection, both women had antibodies capable of neutral-
izing 7 of the 8 primarily Tier 2 viruses tested. Recent studies
suggest that cross subtype breadth is rare before 2 years post-
infection in individuals who are presumably singly infected
[17,32]. Our findings raise the interesting possibility that some
of the individuals identified as having broad responses in prior
screens may have been superinfected.
A few caveats to these findings must be considered. First, there
may have been potential for misclassification of singly infected
women, due to our limit of detection or if recombination occurred
between the initial and superinfecting strains in HIV-1 genomic
regions outside of gag and env [21]. However, this misclassification
would be expected to decrease our ability to detect differences
between superinfected and singly infected women, making it more
likely that the true association between SI and NAb breadth is
stronger than what we observed. Also, we cannot exclude the
possibility that there are other factors involved with the
development of the broad responses in some of the superinfected
women.
This study reveals an unexplored source of naturally-occurring
broadly NAbs, and represents a highly relevant approach to
inform vaccine strategies in three key ways. First, studies on this
and other SI cohorts may provide additional support for
immunizing with particular combinations of different HIV-1
strains could be an effective vaccine approach [33–37]. Given that
the greatest breadth was observed in cases of intersubtype SI, the
use of Env immunogens from different subtypes may be optimal.
Second, the NAbs and viruses isolated from members of this
cohort may hold important clues to antigenic determinants
capable of eliciting cross-reactive antibodies that can protect
against multiple subtypes of HIV-1. Third, longitudinal studies of
superinfected individuals who develop broad and potent NAb
responses, such as those identified here, may foster an under-
standing of the mechanism leading to the elicitation of breadth. Of
particular interest is the observation that two elite neutralizers
developed broad and potent responses soon after infection by a
second HIV-1 strain, suggesting that the processes that lead to the
development of broad HIV-specific NAbs are accelerated by a
second infection. If SI ultimately leads to the rapid capacity of the
overall NAb response to recognize diverse circulating HIV-1
variants, a successful vaccination strategy that mimics natural SI
may lead to the development of broad NAb in immunized
individuals.
Materials and Methods
Ethic statement
The University of Washington’s, University of Nairobi and Fred
Hutchinson Cancer Research Center’s Institutional Review
Boards approved the study. Written informed consent was
provided by all study participants.
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The individuals in this study represent a subset of a prospective
cohort of HIV-1 negative high-risk women from Mombasa, Kenya
[38–40] who have a defined date of infection based on
approximately monthly HIV-1 serology and subsequent retro-
spective RNA testing of banked plasma from time points prior to
seroconversion as described [41]. Twelve superinfected individuals
were identified from a previous screen of 56 women from this
cohort that compared partial env and/or gag sequences amplified
from peripheral blood mononuclear cells (PBMCs) from the first
visit after the detection of seroconversion and a visit during
chronic infection ,5 years later [20–22]. Briefly, single copy PCR
was performed and the sequences from multiple independent
PCRs (median of 7) were examined at each time point. Two
regions of the HIV-1 genome were examined: envelope V1-V5
(,1.2 kb) and gag p17 (,700 bp). Individuals identified as
potential SI cases were further analyzed to verify SI and determine
the interval when it occurred. All cases of SI as well as the
approximate timing of SI were determined by phylogenetic
analysis and allele-specific PCR tailored to the sequences in each
individual. For this study, three singly infected women from the 56
tested for SI in the prior study [20–22], were matched to each of
the 12 cases of SI according to initial infecting viral subtype and
sample availability at time points approximately 5 years post-initial
infection (post-SI) and 1 year prior to SI (pre-SI). In cases where
samples close to 5 years post-initial infection were not available for
the SI case, the closest available sample post-SI was selected and
the timing of sample selection was similar for the controls
(Figure 2). Other than sample availability, the assignment of
controls was random, and was performed using random number
generation. Viral loads were determined by Gen-Probe and were
available for all women, and CD4
+ T cell counts were documented
beginning in 1998 and were available for 17 women prior to SI
and 45 women post SI [42–44]. All women were HIV-1 infected
through heterosexual contact [38], and none reported using
antiretroviral therapy during follow-up for this study.
Heterologous pseudovirus panel
The panel of eight viruses was chosen to include multiple
subtypes with varying neutralization sensitivities to a pool of HIV+
plasma from the Mombasa cohort and monoclonal antibodies (i.e.
b12, 4E10 [45,46]). The viruses used, and their subtypes in
parenthesis, were: SF162 (B) [47], Q461d1 (A) [45], Q842.d16 (A)
[45], QD435.100M.a4 (D) [45], DU156.12 (C) [48],
QC406.70M.f3 (C) [46], Q259.d2.26 (A) [45], Q769.b9 (A) [45].
Plasma was also tested against an envelope from Simian
Immunodeficiency Virus (SIV), SIVmne CL8 [49], to ensure that
the neutralization observed against the virus panel was HIV-1-
specific. The two elite neutralizers identified in the study were also
tested against JR-CSF (B) [50], 6535.3 (B) [51], CAAN5342.A2 (B)
[51], and QB857.23I.B3 (D) [46]. Pseudoviruses were made by
cotransfecting 293 T cells with each of the cloned viral envelopes
listed above and a full-length subtype A proviral clone with a
partial deletion in envelope (Q23Denv), as previously described
[52]. Briefly, an equimolar ratio of envelope-to-provirus plasmid
was added to Fugene-6 transfection reagent (Roche, Indianapolis,
IN) and then incubated with 4 million 293 T cells for 12 hours.
The media was changed at 10 hours. After a total of ,48 hours
post-transfection, supernatants were harvested and filtered
through a 0.22 um Steriflip Filter Unit (Millipore, Billerica, MA)
to remove cellular debris. The resulting pseudoviruses were
screened for infectivity on TZM-bl cells, a HeLa-derived reporter
cell line that expresses high levels of CD4, CCR5, and CXCR4 as
well as B-galactosidase under the transcriptional control of HIV-
LTR [53]. Infectious titers were determined by serially diluting
viruses 10-fold, adding 20,000 TZM-bl cells in growth media
containing 20 ug/mL DEAE-dextran per well, and incubating at
37uC for 48 hours. The cells were then fixed and stained for B-
galactosidase activity and infected cell foci were enumerated
visually.
Neutralization assay
The TZM-bl neutralization assay was used to quantify NAb
breadth as previously described [45]. Briefly, 500 infectious
pseudovirus particles, as determined by the infectioustiter described
above, were incubated in duplicates with 2-fold serial dilutions of
plasma for 1 hour, beginning with an initial concentration of 1:100,
before 10,000 TZM-bl reporter cells per well were added. Each
plasma-virus combination was tested in duplicate and the assay was
repeated twice. Infection levels were determined by B-galactosidase
activity after 48 hours using a chemiluminescent readout. The
IC50, or reciprocal plasma dilution at which 50% of the virus is
neutralized, for each plasma-virus pair was calculated using linear
interpolation from the neutralization curve. In this assay, a plasma
sample was considered to be below the detectable limit of
neutralization for a given virus if the lowest dilution (1:100) did
not show .50% neutralization. With this criterion, plasma samples
that showed neutralization below the limit of detection were
designated an IC50 value of 50, the midpoint between our starting
dilution (1:100) and 0. Each round of assays included HIV-negative
plasma and a HIV-positive plasma pool from 30 HIV-1 infected
individuals in Kenya between 1998–2000 [45] serving as negative
and positive internal controls, respectively. If a run showed
neutralization of the negative control virus (SIVmne CL8) greater
than the limit of detection, we considered that a failed run and
repeated the assay.
Calculation of breadth and potency scores
Results from two independent experiments were averaged on the
log scale before calculating breadth and potency scores. A composite
breadth score for each plasma-virus pair was derived for each
woman by comparing the IC50 for her plasma to the cohort median
IC50 for each virus as described [13]. The cohort median IC50 was
based on all IC50s from the individuals in the study, and this
represented the unique neutralization sensitivity of that virus. If the
IC50s for the given plasma-virus pair was greater than the cohort
median IC50, then individuals were given a score of 1, while those
below were scored as a 0. The overall breadth was then a composite
score for each individual against all eight viruses in the panel, with a
maximum score of 8 and a minimum of 0. We also analyzed our
dataset using the percent neutralization at the first three dilutions in
our assay (1:100, 1:200, 1:400) and applied the same breadth scoring
method. Potency was calculated by dividing the IC50 value for a
given plasma-virus combination by the cohort median IC50 for that
virus. The overall potency was then a composite score for each
individual against all eight viruses in the panel.
A method described in Simek et al, was also applied to the data.
In this method, for each virus, the average log-transformed titer is
calculated for a given sample then scaled to yield a value between
0.0 and 1.0 [9]. As a minor modification to take into account the
varying sensitivities in our virus panel, we divided the average by
the maximum value for the cohort. An average of the scaled
averages across viruses was computed as a final breadth score for
each individual.
Statistical analysis
Breadth scores were analyzed using conditional Poisson
regression, while log transformed potency scores were analyzed
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PLoS Pathogens | www.plospathogens.org 9 March 2012 | Volume 8 | Issue 3 | e1002611usinglinearregressiongeneralizedestimatingequation(GEE).These
models were appropriate given the observed mean-variance
relationships of the breadth and potency scores. The breadth scoring
method described by Simek et al. was analyzed using GEE. All
modelsassessed by GEE used anidentity link,exchangeableworking
correlation structure,and robuststandarderrors.Weused apaired t-
test to compare viral load, CD4+ T cell count and geometric mean
IC50s between superinfected and non-superinfected individuals.
Spearman’srankcorrelationwasused forcomparingtheresultsfrom
our final model and single dilution analysis. Two-tailed P values of
0.05 or less were considered to indicate significance in all statistical
tests. Analyses were performed using STATA statistical software
(version 11, StataCorp, College Station, TX).
Supporting Information
Table S1 Sensitivity analysis to assess whether the association
between SI and NAb breadth was variable depending on the
breadth scoring method or viruses used to test for neutralization
activity. Breadth scores were derived using methods from Simek et
al. and Blish et al. and then compared between superinfected cases
and non-superinfected controls using GEE and Poisson Regres-
sion, respectively. These analyses were further subjected to
examination with a stepwise removal of neutralization data from
one virus at a time and inclusion or exclusion of various
combinations of viruses from the original 8-virus panel. The point
estimates for each scenario described are listed in separate sections
for both Simek and Blish scoring methods.
(PDF)
Table S2 Determining the relationship between SI and NAb
breadth using a breadth scoring method based on the percent
neutralization from a single dilution of plasma (1:100, 1:200, or
1:400). The original RR assessed with breadth scores derived from
IC50s using serial dilutions is listed first for comparison, while the
RRs assessed with breadth scores derived from percent neutral-
ization at a single dilution are listed below.
(PDF)
Table S3 Spearman’s rank correlation between breadth scores
derived from IC50s using serial dilutions versus scores using
percent neutralization at a single dilution.
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